Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
If the ceiling of the total drug costs can be controlled, will Japanese financial authorities tolerate increases in pharmaceutical spending? A health ministry expert panel on October 27 saw a verbal skirmish among former bureaucrats and academics over the concept…
To read the full story
Related Article
- Time Ripe for Debate on Drug Spending Macroeconomic Indexing: INES
June 3, 2026
- Deloitte Proposes Pricing Schemes to Encourage Consolidation of Generic Makers
October 31, 2022
- Think Tanks Propose New Pricing Methods for Innovative Meds, Multi-Faceted Evaluations
October 28, 2022
- Policy Veterans’ Group Advocates Drug Reimbursement at Actual Purchase Prices
October 28, 2022
REGULATORY
- Japan Set to Compile Support Measures to Secure MCMs by Year-End
October 15, 2026
- Japan to Weigh Necessary Measures for FY2027 Revision: PM
October 15, 2026
- Japan Eyes Multi-Year Funding to Secure MCMs: Takaichi
October 14, 2026
- Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
October 13, 2026
- AbbVie’s TrenibotE Up for Review on Oct. 26, Aquipta on Agenda Too
October 13, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…